Entrada Therapeutics (TRDA) Income from Continuing Operations (2020 - 2026)

Entrada Therapeutics has reported Income from Continuing Operations for 7 years, with the latest figure at 39717000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations fell 128.93% year-over-year to 39717000.0; the trailing twelve-month figure through Mar 2026 stood at 166218000.0 (down 772.7% YoY), and the FY2025 full-year result was 143750000.0, down 319.18% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 39717000.0, down from 39196000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 54989000.0 in Q2 2024, with the low at 44180000.0 in Q3 2025.
• Average Income from Continuing Operations over 5 years is 12895705.88, with a median of 21671000.0 recorded in 2022.
• Year-over-year, Income from Continuing Operations soared 452.05% in 2024 and tumbled 3794.25% in 2025.
• Tracing TRDA's Income from Continuing Operations over 5 years: stood at 24629000.0 in 2022, then soared by 61.59% to 9459000.0 in 2023, then jumped by 111.22% to 1061000.0 in 2024, then plunged by 3794.25% to 39196000.0 in 2025, then dropped by 1.33% to 39717000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 39717000.0 (Q1 2026), 39196000.0 (Q4 2025), and 44180000.0 (Q3 2025), per Business Quant data.

Peer Comparison